Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAW039 for moderate to severe atopic dermatitis
NL-OMON40359Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing QAW039 with Placebo (2 arms). Primary endpoints: EASI score at week 12 and Adverse effects. Started Nov 2013; status: active, not recruiting.
02
Drugs
fevipiprant
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON40359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40359.